iSpecimen (NASDAQ:ISPC – Get Rating) had its price target reduced by equities research analysts at EF Hutton Acquisition Corp I from $5.50 to $4.25 in a report issued on Friday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. EF Hutton Acquisition Corp I’s target price indicates a potential upside of 122.51% from the company’s current price.
iSpecimen Price Performance
iSpecimen stock remained flat at $1.91 during trading hours on Friday. 6,986 shares of the company’s stock traded hands, compared to its average volume of 46,357. iSpecimen has a 1 year low of $1.51 and a 1 year high of $28.98. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.12. The stock has a 50 day moving average of $2.25 and a 200-day moving average of $2.87.
iSpecimen (NASDAQ:ISPC – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.30) EPS for the quarter. iSpecimen had a negative return on equity of 36.25% and a negative net margin of 84.89%. The business had revenue of $2.34 million for the quarter.
Institutional Inflows and Outflows
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
- Get a free copy of the StockNews.com research report on iSpecimen (ISPC)
- Why Does Tesla Stock Remain Resilient?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.